Sonia T Anand1, Elizabeth A Chrischilles1, Rebecca J Baer2,3, Mary E Charlton1, Patrick J Breheny4, William W Terry5, Monica R McLemore6, Deborah A Karasek7, Laura L Jelliffe-Pawlowski3,7, Kelli K Ryckman1,5. 1. Department of Epidemiology, University of Iowa, Iowa City, IA, USA. 2. Department of Pediatrics, University of California San Diego, La Jolla, CA, USA. 3. California Preterm Birth Initiative, University of California San Francisco, San Francisco, CA, USA. 4. Department of Biostatistics, University of Iowa, Iowa City, IA, USA. 5. Department of Pediatrics, University of Iowa, Iowa City, IA, USA. 6. Department of Family Health Care Nursing, University of California San Francisco, San Francisco, CA, USA. 7. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Abstract
OBJECTIVE: Leukemia and lymphoma are top cancers affecting children, adolescents and young adults with high five-year survival rates. Late effects of these cancers are a concern in reproductive-age patients, including pregnancy outcomes such as preterm birth. Our study aimed to evaluate whether diagnosis of leukemia or lymphoma prior to pregnancy was associated with preterm birth (<37 weeks gestation). METHODS: We conducted a cross-sectional study using a population-based dataset from California with linked birth certificates to hospital discharge records and an Iowa-based sample that linked birth certificates to Surveillance, Epidemiology, and End Results (SEER) cancer registry data. Preterm birth was defined using birth certificates. We ascertained history of leukemia and lymphoma using discharge diagnosis data in California and SEER registry in Iowa. RESULTS: Prevalence of preterm birth in California and Iowa was 14.6% and 12.0%, respectively, in women with a history of leukemia/lymphoma compared to 7.8% and 8.2%, respectively, in women without a cancer history. After adjusting for maternal age, race, education, smoking, and plurality, Women with history of leukemia/lymphoma were at an increased risk of having a preterm birth in California (odds ratio (OR) 1.89; 95% confidence interval (CI) 1.56-2.28) and Iowa (OR 1.61; 95% CI 1.10-2.37) compared to those with no cancer history. CONCLUSION: In both California and Iowa, women with a history of leukemia or lymphoma were at increased risk for preterm birth. This suggests the importance of counseling with a history of leukemia/lymphoma prior to pregnancy and increased monitoring of women during pregnancy.
OBJECTIVE: Leukemia and lymphoma are top cancers affecting children, adolescents and young adults with high five-year survival rates. Late effects of these cancers are a concern in reproductive-age patients, including pregnancy outcomes such as preterm birth. Our study aimed to evaluate whether diagnosis of leukemia or lymphoma prior to pregnancy was associated with preterm birth (<37 weeks gestation). METHODS: We conducted a cross-sectional study using a population-based dataset from California with linked birth certificates to hospital discharge records and an Iowa-based sample that linked birth certificates to Surveillance, Epidemiology, and End Results (SEER) cancer registry data. Preterm birth was defined using birth certificates. We ascertained history of leukemia and lymphoma using discharge diagnosis data in California and SEER registry in Iowa. RESULTS: Prevalence of preterm birth in California and Iowa was 14.6% and 12.0%, respectively, in women with a history of leukemia/lymphoma compared to 7.8% and 8.2%, respectively, in women without a cancer history. After adjusting for maternal age, race, education, smoking, and plurality, Women with history of leukemia/lymphoma were at an increased risk of having a preterm birth in California (odds ratio (OR) 1.89; 95% confidence interval (CI) 1.56-2.28) and Iowa (OR 1.61; 95% CI 1.10-2.37) compared to those with no cancer history. CONCLUSION: In both California and Iowa, women with a history of leukemia or lymphoma were at increased risk for preterm birth. This suggests the importance of counseling with a history of leukemia/lymphoma prior to pregnancy and increased monitoring of women during pregnancy.
Authors: Johanna Melin; Sirpa Heinävaara; Nea Malila; Aila Tiitinen; Mika Gissler; Laura Madanat-Harjuoja Journal: Int J Cancer Date: 2018-11-26 Impact factor: 7.396
Authors: Laura-Maria Madanat-Harjuoja; Nea Malila; Päivi M Lähteenmäki; John D Boice; Mika Gissler; Tadeusz Dyba Journal: Int J Cancer Date: 2010-10-01 Impact factor: 7.396
Authors: Chelsea Anderson; Stephanie M Engel; Jennifer E Mersereau; Kristin Z Black; William A Wood; Carey K Anders; Hazel B Nichols Journal: JAMA Oncol Date: 2017-08-01 Impact factor: 31.777
Authors: Patricio Lopez-Jaramillo; Juan Barajas; Sandra M Rueda-Quijano; Cristina Lopez-Lopez; Camilo Felix Journal: Front Physiol Date: 2018-12-19 Impact factor: 4.566